RESUMO
BACKGROUND: Diagnostic criteria are used to identify a patient having a disease in a clinical setting, whereas classification criteria create a well-defined population for research purposes. The diagnosis and classification of amyopathic dermatomyositis (ADM) have not been recognized by most existing criteria for idiopathic inflammatory myopathies (IIMs). To address this, several criteria were proposed to define ADM either as a distinct disease entity or as a subset of the spectrum of IIMs. OBJECTIVES: To discuss the diagnosis and classification of ADM and to assesses the available criteria in identifying cases of ADM and/or distinguishing it from dermatological mimickers such as lupus erythematosus. METHODS: We conducted an extensive literature search using the PubMed database from June 2016 to August 2018, using the search terms 'amyopathic dermatomyositis', 'diagnosis' and 'classification'. RESULTS: The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria, which are the only validated classification criteria for adult and juvenile IIM and their major subgroups, include three cutaneous items (Göttron sign, Göttron papules, heliotrope rash) to be able to classify ADM. This international and multispecialty effort is a huge step forward in the classification of skin-predominant disease in dermatomyositis. However, about 25% of the population with ADM do not meet two out of the three skin features and are misdiagnosed or classified as having a different disease entity, most commonly lupus erythematosus. CONCLUSIONS: These gaps rationalize the continuous assessment and improvement of existing criteria and/or the development of validated, separate and skin-focused criteria for DM.
Assuntos
Dermatomiosite/diagnóstico , Lúpus Eritematoso Cutâneo/diagnóstico , Dermatologia/história , Dermatomiosite/classificação , Dermatomiosite/imunologia , Dermatomiosite/patologia , Diagnóstico Diferencial , História do Século XX , História do Século XXI , Humanos , Lúpus Eritematoso Cutâneo/imunologia , Lúpus Eritematoso Cutâneo/patologia , Reumatologia/história , Pele/imunologia , Pele/patologiaRESUMO
An MDHAQ/RAPID3 (multidimensional health assessment questionnaire/routine assessment of patient index data) was developed from the HAQ over 25 years, based on observations made from completion by every patient (with all diagnoses) at every routine rheumatology visit since 1980. Modification of the HAQ was viewed as similar to improving a laboratory test, with a primary focus on clinical value for diagnosis, prognosis, and/or management, as well as feasibility for minimal effect on clinical workflow. Rigorous attention, was also directed to validity, reliability, other methodologic and technological considerations, but after clinical value and feasibility were established. A longer "intake" MDHAQ was introduced for new patients to record a complete past medical history - illnesses, hospitalisations, surgeries, allergies, family history, social history and medications. MDHAQ scales not found on the HAQ record complex activities, sleep quality, anxiety, depression, self-report joint count, fatigue, symptom checklist, morning stiffness, exercise status, recent medical history, social history and demographic data within 2 pages on one sheet of paper. An electronic eMDHAQ/RAPID3 provides a similar platform to pool data from multiple sites. A patient may be offered a patient-administered, password-protected, secure, web site, to store the medical history completed on the eMDHAQ. This eMDHAQ would allow a patient to complete a single general medical history questionnaire rather than different intake questionnaires in different medical settings. The eMDHAQ would be available for updates and correction by the patient for future visits, regardless of electronic medical record (EMR). The eMDHAQ is designed to interface with an EMR using HL7 (health level seven) and SMART (Substitutable Medical Apps, Reusable Technology) on FHIR (Fast Healthcare Interoperability Resources), although implementation requires collaboration with the EMR vendor. Advanced features include reports for the physician formatted as a medical record note of past medical history for entry into any EMR without typing or dictation, and a periodic "tickler" function to monitor long-term outcomes with minimal effort of the physician and staff. Nonetheless, clinical use of an eMDHAQ should be guided primarily not by the latest technology, but by value and feasibility in clinical care, the same principles that guided development of the pencil-and-paper MDHAQ/RAPID3.
Assuntos
Artrite Reumatoide/diagnóstico , Registros Eletrônicos de Saúde/tendências , Indicadores Básicos de Saúde , Melhoria de Qualidade/tendências , Indicadores de Qualidade em Assistência à Saúde/tendências , Reumatologia/tendências , Inquéritos e Questionários , Telemedicina/tendências , Artrite Reumatoide/fisiopatologia , Artrite Reumatoide/psicologia , Artrite Reumatoide/terapia , Lista de Checagem , Atenção à Saúde/tendências , Difusão de Inovações , Avaliação da Deficiência , Registros Eletrônicos de Saúde/história , Previsões , Pesquisa sobre Serviços de Saúde/tendências , Nível de Saúde , História do Século XX , História do Século XXI , Humanos , Medidas de Resultados Relatados pelo Paciente , Valor Preditivo dos Testes , Prognóstico , Melhoria de Qualidade/história , Indicadores de Qualidade em Assistência à Saúde/história , Reprodutibilidade dos Testes , Reumatologia/história , Índice de Gravidade de Doença , Telemedicina/história , Fatores de TempoRESUMO
OBJECTIVE: The Rheumatology Research Foundation's Clinician Scholar Educator (CSE) award is a 3-year career development award supporting medical education research while providing opportunities for mentorship and collaboration. Our objective was to document the individual and institutional impact of the award since its inception, as well as its promise to strengthen the subspecialty of rheumatology. METHODS: All 60 CSE Award recipients were surveyed periodically. Fifty-six of those 60 awardees (90%) responded to requests for survey information that included post-award activities, promotions, and further funding. Data were also collected from yearly written progress reports for each grant. RESULTS: Of the total CSE recipients to date, 48 of 60 (80%) are adult rheumatologists, 11 of 60 (18%) are pediatric rheumatologists, and 1 is an adult and pediatric rheumatologist. Two-thirds of survey respondents spend up to 30% of their total time in educational activities, and one-third spend greater than 30%. Thirty-one of the 60 CSE recipients (52%) have published a total of 86 medical education papers. Twenty-six of 52 (50%) had received an academic promotion following the award. Eleven awardees earned advanced degrees. CONCLUSION: We describe the creation and evolution of a grant program from a medical subspecialty society foundation and the impact on producing education research, individual identity formation, and ongoing support for educators. This community of rheumatology scholar educators now serves as an important resource at the national level for the American College of Rheumatology and its membership. We believe that this grant may serve as a model for other medical societies that want to promote education scholarship and leadership within their specialties.
Assuntos
Distinções e Prêmios , Pesquisa Biomédica/educação , Reumatologia/educação , Sociedades Médicas/história , Adulto , Bolsas de Estudo , Feminino , História do Século XXI , Humanos , Liderança , Masculino , Reumatologia/históriaRESUMO
The origins of anti-rheumatic therapy are very old and mainly related to the use of traditional, sometimes extravagant, treatments, as a part of folk medicine. Spa therapy has long been used for the treatment of rheumatic diseases, as well as, in later times, physical treatments, including electrotherapy. Drug treatment has developed beginning from substances of vegetable origin, such as willow and colchicum extracts. Then it has been spread out through the chemical synthesis of compounds with specific action and therefore more effective, owing to the great development of pharmaceutical industry.
Assuntos
Antirreumáticos/história , Indústria Farmacêutica/história , Homeopatia/história , Medicina Tradicional/história , Especialidade de Fisioterapia/história , Reumatologia/história , Aspirina/história , Balneologia/história , Terapia por Estimulação Elétrica/história , Europa (Continente) , História do Século XV , História do Século XVI , História do Século XVIII , História do Século XIX , História do Século XX , História Antiga , História Medieval , Humanos , Medicina Arábica/história , Modalidades de Fisioterapia/história , Estados UnidosRESUMO
Rheumatology program at Tehran University was established by Fereydoun Davatchi in 1969. Later, Reza Moghtader, Firouz Panahi, and Amir-Khan Chafizadeh joined him. The first rheumatology outpatient clinic was founded in 1970. In 1974, the first rheumatology fellowship department was established along with a small research laboratory. The department expanded gradually to become the Rheumatology Research Center (RRC) in 1981. RRC was officially recognized in 1994 by the Ministry of Health and in 2001 as the Center of Excellence for Rheumatology in Iran. There are 15 rheumatologists who are the teaching staff at RRC. The center has trained up to 45 rheumatologists since 1985. RRC has conducted about 150 research projects (national and international collaborative projects). It has published 14 yearly books and collaborated in the publication of seven international books. RRC has presented 207 papers in local and 337 papers in international conferences. RRC has published 50 papers in local and 178 papers in international journals.
Assuntos
Reumatologia/história , Bolsas de Estudo , História do Século XX , Humanos , Irã (Geográfico) , Publicações , Ensino , Universidades/históriaRESUMO
Some important discoveries in the history of rheumatology happened during war periods. It is well known that arthritis associated with conjunctivitis and urethritis, following dysenteric episodes, has been described during the First World War from the German Hans Reiter and, nearly contemporarily, from the French Nöel Fiessinger and Edgar Leroy. Less known is instead the fact that the first cases of sympathetic algoneurodystrophy have been reported by the American Silas Weir Mitchell in soldiers wounded by fire-arms, during the Civil War of Secession. Other war episodes have been crucial for the development of some drugs now abundantly applied to the care of rheumatic diseases. The discovery of therapeutic effects of immunosuppressive agents, in fact, happened as an indirect consequence of the use of poison gas, already during the First World War (mustard gas), but above all after an episode in the port of Bari in 1943, where an American cargo boat was sunk. It had been loaded with a quantity of cylinders containing a nitrogenous mustard, whose diffusion in the environment provoked more than 80 deaths owing to bone marrow aplasia.Moreover, the history of the cortisone shows a strict link to the Second World War, when Germany imported large quantities of bovine adrenal glands from Argentina, with the purpose of producing some gland extracts for the Luftwaffe aviators, in order to increase their performance ability.
Assuntos
Anti-Inflamatórios/história , Cortisona/história , Imunossupressores/história , Doenças Reumáticas/história , Reumatologia/história , Guerra , Guerra Civil Norte-Americana , Animais , Anti-Inflamatórios/uso terapêutico , Artrite Reativa/história , Bovinos , Cortisona/uso terapêutico , Indústria Farmacêutica/história , Alemanha , História do Século XIX , História do Século XX , Humanos , Imunossupressores/uso terapêutico , Medicina Militar/história , Distrofia Simpática Reflexa/história , Doenças Reumáticas/tratamento farmacológico , Reino Unido , Estados Unidos , I Guerra Mundial , II Guerra MundialRESUMO
During our careers, we have developed new and innovative concepts pertaining to the pathophysiology of osteoarthritis which have assisted in the development of new therapeutic approaches. Moreover, our laboratory has long sought to develop protective agents for osteoarthritic structural joint tissues. The most significant concepts that have originated from our lab are briefly outlined in this commentary.